Drug Safety
Equibles does not estimate personal net worth.
Get an email with a short summary when Kyntra Bio, Inc. publishes a filing, an earnings call transcript or a press release.
Get KYNB alertsAbout Drug Safety
The proxy statement of Kyntra Bio, Inc. reports total compensation of $4,985,088 for Drug Safety in fiscal 2019, including a base salary of $550,000. Disclosed compensation is on record for 2 fiscal years. Kyntra Bio, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Kyntra Bio, Inc. includes James A. Schoeneck (CEO), Thane Wettig (CEO and Board Member), Thomas B. Neff (CEO) and 4 others.
Affiliation history
-
Kyntra Bio, Inc. (KYNB)
Proxy statement
Current
Company network
Leadership on record at Kyntra Bio, Inc.
- James A. Schoeneck CEO
- Thane Wettig CEO, Board Member
- Thomas B. Neff CEO
- Jim Schoeneck Chairman
- David DeLucia CFO
- Andrew E. Singer Board Member
- Michael Kauffman, M.D., Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2019 | Kyntra Bio, Inc. (KYNB) | and Pharmacovigilance | $550,000 | $4,985,088 |
| 2018 | Kyntra Bio, Inc. (KYNB) | and Pharmacovigilance | — | — |
Recent activity
No call appearances or filed executive changes recorded yet.